I was pleased to see that Cytodyn is adhering (for the most part) to their PR schedule. The substance of the LTS aside, the effort to keep shareholders informed regularly shows consideration for investor stakeholders. Many things are out of management's hands. Keeping shareholders informed as they expect, is something they can control. As they say in baseball, "we're producers, not directors".